Asset 1 Asset 1 Asset 1 Asset 1 Asset 1 Asset 1 Asset 1 Asset 1 Asset 1
mobile-ornament mobile-ornament mobile-ornament mobile-ornament mobile-ornament mobile-ornament mobile-ornament mobile-ornament mobile-ornament
Asset 2 Asset 2 Asset 2 Asset 2 Asset 2 Asset 2 Asset 2 Asset 2 Asset 2
Asset 3 Asset 3 Asset 3 Asset 3 Asset 3 Asset 3 Asset 3 Asset 3 Asset 3
Blog & News

The Stars Impact of the CY2019 CMS Final Call Letter

Guest blog contributor:

Rex Wallace – Principal, Rex Wallace Consulting, LLC

 
On April 2nd, the Centers for Medicare and Medicaid Services (CMS) released the Announcement of Calendar Year (CY) 2019 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter. The entire document is a behemoth which includes important information about CY2019 for Medicare Advantage plans across a variety of topics. This post will focus solely on the impact on Star Ratings.

var so = new SWFObject(‘/tasks/widgets/ckeditor/plugins/media/mediaplayer-5.4/player.swf’,’player_1524079967169′,’320′,’180′,’9′);
so.addParam(‘allowfullscreen’,’true’);
so.addParam(‘allowscriptaccess’,’always’);
so.addParam(‘wmode’,’opaque’);
so.addVariable(‘replacement’,’/tasks/widgets/ckeditor/plugins/media/images/replacement.gif’);
so.addVariable(‘plugins’,’gapro-1′);
so.addVariable(‘gapro.accountid’,’UA-XXXXXXX-X’);
so.addVariable(‘file’,’/default/assets/Image/Rex%20Wallace%20.png’);
so.write(‘media_1524079967169’);

The release of the Final Call Letter is one of a series of key milestone dates leading up to October 11, 2018, when CMS releases Star Ratings for each Medicare Advantage organization to the public.

IMPACT ON THE 2019 STAR RATINGS

 

NEW MEASURES FOR 2019 STARS

New!

New!

Statin User in Persons with Diabetes (SUPD) (Part D)

Statin Therapy for Patients with Cardiovascular Disease (Part C)

 

NEW: Statin Use in Persons with Diabetes (SUPD) (Part D)

CMS will add SUPD to the 2019 Star Ratings with a weight of 1. Beginning with the 2020 Star Ratings, CMS proposes that this PQA intermediate outcome measure will have a weight of 3. The Holy Trinity of triple-weighted Part D measures has officially become the Mt. Rushmore.

NEW: Statin Therapy for Patients with Cardiovascular Disease (Part C)

This NCQA HEDIS measure is currently included as a display measure. CMS is adding it to the 2019 Star Ratings as a process measure with an ongoing weight of 1.

REMOVAL OF MEASURES FOR 2019 STARS

REMOVAL!

Beneficiary Access and Performance Problems (BAPP) (Part C & D)

 

REMOVAL: Beneficiary Access and Performance Problems (BAPP) (Part C & D)

Although CMS received mixed responses from advocacy groups (opposed to removing BAPP) and health plans (supportive of removing BAPP), it will proceed in retiring the current BAPP measure for 2019 Stars. A revised BAPP measure including only CAM data (CAM score will be the only deduction) will hit the display page for 2019. No official word on when this measure will become an official Stars measure again.

 NOTE: Reducing the Risk of Falling (Part C)

 Is staying. Vacation was officially cancelled for this HOS measure   which was scheduled to be removed temporarily for 2019.   Responders convinced CMS to leave it on. And note only is it   staying on, it will continue impacting the all-important Part C   Improvement Measure for 2019.

 

CHANGES TO MEASURES FOR 2019 STARS

CHANGING: Improvement Measures (Part C & D)

Below are the changes regarding which measures are included in the Improvement Measures for 2019 Stars as compared to 2018 Stars. Some of this is elementary regarding the treatment of measures new to Stars or being removed, but I’ll err on the side of overcommunicating. One change from the Advance Notice is that – as mentioned above – the HOS measure, Reducing the Risk of Falling, which was originally proposed to be removed from the 2019 Star Ratings and thus, Improvement Measure inclusion, is now staying.

2019 MEASURE CHANGES IMPACTING THE IMPROVEMENT MEASURE

2018 STARS

2019 STARS

 Improving Bladder Control

No

Yes

 Reducing the Risk of Falling

Yes

Yes

 Beneficiary Access and   Performance Problems

No

No (Removal)

 Medication Reconciliation Post-   Discharge

No

Yes

 Getting Appointments and Care     Quickly

No

Yes

 Customer Service

No

Yes

 Care Coordination

No

Yes

 Statin Therapy for Patients with   Cardiovascular Disease

No (Was Not Official Measure)

No (1st Year as Official Measure)

 Statin Use in Persons with Diabetes

No (Was Not Official Measure)

No (1st Year as Official Measure)

 

CHANGING: Medication Adherence (ADH) for Hypertension (RAS Antagonists), Medication Adherence for Diabetes Medications (Part D)

For 2019 Stars, CMS will expand its data sources for identifying all Part D enrollees with ESRD for exclusion from the measures to include ICD-10-CM codes found in both Part A & B claims and Risk Adjustment Processing System (RAPS) RxHCCs.

CHANGING: Medication Adherence (ADH) for Hypertension (RAS Antagonists), Medication Adherence for Diabetes Medications, and Medication Adherence for Cholesterol (Statins) (Part D)

CMS will implement a simpler approach to count the day of discharge in the PDC adjustment for 2019 Stars.

CHANGING: Members Choosing to Leave the Plan (Part C & D)

CMS is expanding the exclusions to include plan benefit package (PBP) service area reductions (SARs).

CHANGING: Reducing the Risk of Falling (Part C)

You’d better update your dashboards for 2019 Stars forecasts, because the “Falls” measure failed to fall off. CMS had planned to remove it from 2019 and 2020 Stars due to a denominator expansion. However, many commenters urged CMS to leave it on, fearing that taking it off would send the signal that falls prevention is not important. CMS will keep it on for 2019 and 2020 Stars.

ADDITIONAL IMPLICATIONS FOR 2019 STARS

Contract Consolidations and Quality Bonus Payments. CMS is proposing rules that would prevent plans who have taken advantage of the Quality Bonus Payment (QBP) loopholes which have allowed them to merge large under-performing contracts into tiny high-performing contracts, reaping huge financial gains and creating – some say – an unfair playing field.

Proposed Scaled Reductions for Appeals IRE Data Completeness Issues. CMS proposed a new process to determine and apply reductions to the four appeals measures based on findings that the underlying data are inaccurate, biased, or incomplete. CMS plans to provide plans with a preview of the data before the Star Ratings are finalized.

Disaster Implications. Natural disasters significantly affected many Medicare Advantage organizations and their beneficiaries in 2017. The Final Call Letter includes much information about certain 2019 Stars changes for affected organizations. Here, I will call out a few key ways these changes are impacting all other organizations.

  • CMS will exclude impacted plans from many cut-points and Reward Factor calculations

  • i.e., plans operating solely in Puerto Rico or with 60% or more of their enrollees in FEMA-designated Individual Assistance areas at the time of the disaster

  • These contracts will be excluded to ensure that any impact of the disaster on their measure-level scores will not have an impact on the cut points for other contracts.

  • CMS examined the data from the previous year’s Star Ratings; states that this change last year would have resulted in a “very similar” distribution of 2018 Star Ratings.

NEW 2019 DISPLAY MEASURE

NEW: Plan Makes Timely Decisions about Appeals (Part C). CMS plans to include a new appeal measure for the 2019 and 2020 display pages which includes cases dismissed by the IRE because the plan has subsequently approved coverage/payment. These cases are currently excluded which could artificially improve performance. CMS plans to make this a 2021 Stars measure, at which time the current measure would be retired.

CHANGES TO EXISTING 2019 DISPLAY MEASURES

CHANGING: Hospitalizations for Potentially Preventable Complications (Part C). Stakeholder concerns led NCQA to consider updates to this measure. CMS will retain this measure on the 2019 display page and propose it as a 2022 Stars measure with a first-year weight of 1 and weight of 3 thereafter.

CHANGING: High Risk Medication (HRM) (Part D). This PQA measure will remain on the 2019 display page with an updated drug list and recent PQA specification change.

CHANGING: Drug-Drug Interactions (DDI) (Part D). Implementing the PQA updated drug list for the 2019 display page.

CHANGING: Antipsychotic Use in Persons with Dementia (APD) (Part D). On the 2019 display page, CMS proposes to display the rates for the two population breakouts (community-only and long-term nursing home residents) as well as the overall APD rate. CMS will consider making APD a future Stars measure.

CHANGING: Use of Opioids from Multiple Providers and/or at High Dosage in Persons without Cancer (Part D). PQA has proposed several changes to these measures. CMS is implementing the changes into the 2017 Patient Safety reports and adding some of the changes to the 2019 display page. Once PQA finalizes the updated measure specifications, CMS will consider these as future Stars measures.

2019 DISPLAY MEASURES BEING RETIRED

RETIRING: Enrollment Timeliness (Part C and D). Due to high performance across most plans, CMS is removing this measure from the display page. However, they encourage contracts to continue to perform highly in spite of the fact that public accountability will no longer exist.

RETIRING: Appropriate Monitoring of Patients Taking Long-term Medications and Asthma Medication Ratio (Part C). NCQA removed the Medicare population from these measures, which will result in their removal from the display page beginning in 2019.

POTENTIAL IMPACT ON THE 2020 STAR RATINGS

Now, let’s look ahead to the 2020 Star Ratings, which requires that we also look back, because the measurement period began four months ago.

POTENTIAL CHANGES TO EXISTING MEASURES FOR 2020 STARS

Controlling High Blood Pressure (Part C). NCQA is exploring modifications to this heavyweight measure that is currently entirely – and maddeningly – based on medical records.  Fingers are crossed that NCQA finds a way to allow plans to close this gap with administrative data.

Plan All-Cause Readmissions (Part C). NCQA and CMS are exploring several revisions to this HEDIS measure. The revised measure would be on the display page for 2019 and 2020, then it would become part of 2021 Stars (weight of 1 the first year; weight of 3 thereafter). The current measure would remain through 2020 Stars.

Initiation and Engagement in Alcohol or Drug Dependence (AOD) Treatment (Part C). NCQA made minor modifications to this display page, and CMS is asking for plans to provide feedback on other potential changes.

Telehealth and Remote Access Technologies (Part C). CMS requests feedback to share with NCQA on feasibility of and strategies for addressing telehealth services, especially regarding the following measures:

  • Use of Spirometry Testing in the Assessment and Diagnosis of COPD

  • Adults’ Access to Preventive/Ambulatory Health Services

  • Controlling High Blood Pressure

  • Comprehensive Diabetes Care

Cross-Cutting Exclusions for Advanced Illness (Part C). NCQA is evaluating the clinical appropriateness and feasibility of excluding individuals with advanced illness from selected HEDIS measures. NCQA is exploring which specific illnesses and healthcare utilization may warrant an exclusion and to which measures the exclusion should be applied. If approved, updates to HEDIS measures for any additional exclusions would be incorporated in HEDIS 2019.

Medication Adherence (ADH) for Cholesterol (Statins) (Part D). CMS plans to apply the ESRD exclusion to 2020 Stars that PQA implemented for this measure for 2018.

Medication Therapy Management (MTM) Program Completion Rate for Comprehensive Medication Reviews (CMR) Measure (Part D). CMS plans to apply a new denominator exception to 2020 Stars that PQA implemented for this measure for 2018.

MPF Price Accuracy (Part D). CMS will implement the following changes for the 2020 and 2021 display page, potentially including it in 2022 Stars:

  • Factor both how much and how often prescription drug event (PDE) prices exceeded the prices reflected on the MPF.

  • Increase the claims included in the measure.

Center for Medicare and Medicaid Innovation Model Tests. Some stakeholders have expressed concern regarding the potential for improvements resulting from VBID and Enhanced MTM participation to adversely influence the Star Ratings of contracts that are ineligible to participate. CMS is considering excluding VBID and Enhanced MTM participants from cut-point calculations for relevant measures, or possibly establishing different cut-points for participants.

    POTENTIAL NEW MEASURES FOR 2020
    STARS AND BEYOND

    Transitions of Care (Part C). CMS plans to include this measure on the 2020 display page and potentially include in 2022 Stars.

    Follow-up after Emergency Department Visit for Patients with Multiple Chronic Conditions (Part C). CMS plans to include this measure on the 2020 display page and potentially include in 2022 Stars.  

    Care Coordination Measures (Part C). CMS has identified potential new care coordination measures and is currently testing them for possible future implementation.

    Opioid Overuse (Part C). Measures still being developed; no current plans to add these to the display page or Star Ratings.

    Assessment of Care for People with Multiple High-Risk Chronic Conditions (Part C). The measure concept is currently undergoing testing to assess feasibility, alignment with current practice, and gaps in care.

    Depression Screening and Follow-Up for Adolescents and Adults (Part C). Depending on the results during the first year of implementation, CMS may consider this measure for the display page and Star Ratings in the future.

    Unhealthy Alcohol Use Screening and Follow-Up (Part C). CMS may consider this measure for the display page and Star Ratings in the future.

    Readmissions from Post-Acute Care (Part C). If approved, the new measure or revisions to the current PCR measure would be included in HEDIS 2019.

    Adult Immunization Measure (Part C). If approved, the new measure would be included in HEDIS 2019. Depending on results of implementation, CMS will determine the use of this new composite measure for the display page and Star Ratings for the future.

    Anxiety (Part C). Any new anxiety quality measures or changes for the depression measures would be included in HEDIS 2020 at the earliest.

    Polypharmacy Measures (Part D). PQA developed three measures that identify potentially harmful concurrent drug use or polypharmacy. CMS is reviewing these measures for potential inclusion in Patient Safety reporting, display page, or Star Ratings in the future.

    Additional PQA Medication Adherence Measures (Part D). CMS evaluated two additional PQA endorsed medication adherence measures but will not add them to the Patient Safety reports, the display page, or Star Ratings at this time.


    Rex Wallace is Principal at Rex Wallace Consulting, LLC. His firm is dedicated to helping Medicare Advantage plans improve Star Ratings. Prior to founding Rex Wallace Consulting, Rex held Consumer Experience and Star Ratings leadership roles at Cambia Health Solutions and Universal American. He is an esteemed expert in the Medicare space. 


    To learn more about how Advanced Plan for Health provides our Medicare clients with the visibility they’ve been missing via our advanced and predictive analytics, or to learn more about our The RISE Association (Resource Initiative & Society for Education) Medicare Advantage research study, please contact us here, email marketing@mypoindexter.com or call 888-600-7566.

    Share

    More Articles

    1. The 2020 American Drug Shortage

      In the soon to be 244 years of Independence, the United States of America has been tested beyond measure on countless occasions, and each time Americans have risen to the occasion. Now, America is facing a monumental challenge yet again in a…

      Read More »
    2. What Benefits Managers Can Do Today to Immediately Reduce Healthcare Costs

      Identifying health plan risks is a multi-faceted, complex and daunting undertaking for self-insured companies who wish to proactively mitigate rising healthcare costs. However, even those employers who haven’t invested in claims data analysis can make quick, significant gains by addressing population health…

      Read More »
    3. 7 Considerations Self-Funded Groups Should Address Post COVID19

      With every crisis there comes opportunity, and the current pandemic our world is enduring is no different. The Corona crisis has provided every steward of health with a growing list of opportune lessons from which to learn. In particular, self-funded groups have…

      Read More »
    4. Data: Your Secret Weapon

      Everyone will claim to have data analytics tools for population health management, but not all are created equal.  What if…You could find everyone with metabolic syndrome, or another chronic condition, that badly needs an  intervention to avoid hospitalization with just a few…

      Read More »

    Looking
    for more?

    Check out our Resource Center for
    infographics, white papers, and more.

    GO THERE

    Seen
    enough?

    We’re ready to get started! Contact us to see
    what APH can do for you and your business.

    CONTACT US